Study Phase 3

An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia

  • PDF icon for CSR Summary CSR Summary
  • Globe symbol for NCT Number NCT Number Not Available
  • Notebook for Primary Citation Primary Citation Trial has yet to be published
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment330% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-USA-70 (EXTENSION OF RIS-USA-63) CR003361, RIS-USA-T216Data PartnerJohnson & JohnsonCondition StudiedDementiaMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.